Published in AIDS Weekly, August 26th, 1996
This follows the recommendation of the EU's scientific advisory committee, the Committee for Proprietary Medicinal Products, which voted on April 18, 1996, in favor of the approval of Epivir. In the European Union, Epivir is indicated in combination with other antiretroviral agents for the treatment of HIV infected adults and children of 12 years of age and over, with progressive immunodeficiency (CD4 counts of 500 cells/mm3 or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.